{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:38Z","timestamp":1777934438198,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Conventional first-line therapy for squamous cell carcinoma of anal canal is definitive chemoradiotherapy with a curative intent. Due to the efficacy of treatment for locoregional disease and rarity of metastatic anal carcinoma, clinical trial data for treatment of metastatic disease is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>Herein, we describe a patient with relapsed, metastatic squamous cell carcinoma of the anal canal treated with cetuximab as the third-line therapy. Management and outcome: The patient responded to this pharmacological agent, meeting the definition of a partial response per response evaluation criteria in solid tumors (RECIST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>EGFR inhibitors are potential avenues for the subsequent lines of therapy in metastatic or relapsed\/refractory anal cancer. Prospective clinical trials of cetuximab alone or in combination with other agents are warranted in this setting in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219884605","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T02:17:38Z","timestamp":1572920258000},"page":"1025-1028","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-9737","authenticated-orcid":false,"given":"Jaren","family":"Lerner","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Eisenhower Health, Rancho Mirage, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4202-8098","authenticated-orcid":false,"given":"Miguel","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Eisenhower Health, Rancho Mirage, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-8394","authenticated-orcid":false,"given":"Constantin A","family":"Dasanu","sequence":"additional","affiliation":[{"name":"Eisenhower Lucy Curci Cancer Center, Rancho Mirage, USA"},{"name":"UC San Diego Health, San Diego, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"bibr1-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2016.07.001"},{"key":"bibr2-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.01.007"},{"key":"bibr3-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.12.029"},{"key":"bibr4-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1667"},{"key":"bibr5-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1159\/000259615"},{"key":"bibr6-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28045"},{"key":"bibr7-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt368"},{"key":"bibr8-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.029"},{"key":"bibr9-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1642"},{"key":"bibr10-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-014-9626-7"},{"key":"bibr11-1078155219884605","doi-asserted-by":"publisher","DOI":"10.1159\/000452766"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219884605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219884605","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219884605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:07Z","timestamp":1777688527000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219884605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1177\/1078155219884605"],"URL":"https:\/\/doi.org\/10.1177\/1078155219884605","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]}}}